Business & Biotech

Partnering remains one of the most important activities for an emerging company to build and grow its business. Finding a good partner does not have to be an arcane process. With the proper steps, a good partner will emerge from the myriad opportunities that exist.

The biotech industry needs a consistent supply of well-educated graduates to continue to deliver on the promise of innovation to help heal, fuel and feed the world. Academic-industry partnerships can encourage students to pursue careers in biotech by bringing real world examples and inspiration from the front lines into the classroom.

Mark Herzog, Executive Director, Virginia Biotechnology Association

Podcast with Mark Herzog, Executive Director of Virginia Biotechnology Association

BIOtech-Now recently spoke with Mark Herzog of VaBIO, check out the podcast here. Additionally, Herzog shared the latest on biotech in Virginia in the Q&A below.

Building and sustaining a successful, innovative biotech sector is a complex process that needs active support from government, policymakers, academia, the financial community and others. Investment in biotechnology has the potential for significant Return on Investment through the creation of high skill, high wage jobs in addition to bringing innovations to market that will help to heal, fuel and feed the world.

Until a decade ago, the U.S. was the undisputed leader in biotechnology development. Since then, global competition for the industry has rapidly increased.

BIO hosted a media briefing on Wednesday, June 30th, with Jim Greenwood and Rachel King, Co-Founder and CEO of GlycoMimetics, Inc. and member of BIO’s Executive Committee.

BIOtechNow’s Tracy Krughoff talks to Dr. Louise Perkins, Chief Scientific Officer at the Multiple Myeloma Research Foundation. The Multiple Myeloma Research Foundation is one of the advocacy organizations presenting at the upcoming BIO CEO & Investor Conference, being held February 8-9 in New York City.

Listen to the podcast here:
http://www.bio.org/podcasts/MMRF.wma

This week, IP Watchdog sets the story straight by writing a post, “Fact vs. Fiction: The Truth on Biologics and Biosimilars raising some important points,

“Did you know that on average, it takes an investment of more than $1 billion over 10 years to develop a biotech medicine.

This week Health Reform Watch wonders if the biosimilars debate is over.

"Two months ago, I discussed possible federal legislation intended to balance the competing need for scientific and medical innovation with the costs to patients for biosimilars.

This week,

“To continue the state life science industry's record-setting growth rate, the North Carolina Biotechnology Center, with the help of statewide partners, is building an addition to its Research Triangle Park headquarters.”

To find out more about this check out the Web site of the North Carolina Biotechnology Center.

Also this week, Patent Docs wrote about a media briefing we (BIO)

For people living in the world’s richest countries, the quality of health care has been rising for decades.  But in the developing world, diseases like cholera, dengue fever, and leishmaniasis are endemic.  These illnesses are contracted by the world’s poorest each day, causing social, political, and economic devastation that exte